Related Experiment Video
Updated: May 13, 2026
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
Published on: September 29, 2014
Animal models for metabolic, neuromuscular and ophthalmological rare diseases
Guillaume Vaquer1, Frida Rivière, Maria Mavris
1Human Medicines Special Areas, Human Medicines Development and Evaluation, European Medicines Agency, London E14 4HB, UK.
Abstract:
Animal models are important tools in the discovery and development of treatments for rare diseases, particularly given the small populations of patients in which to evaluate therapeutic candidates. Here, we provide a compilation of mammalian animal models for metabolic, neuromuscular and ophthalmological orphan-designated conditions based on information gathered by the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) since its establishment in 2000, as well as from a review of the literature. We discuss the predictive value of the models and their advantages and limitations with the aim of highlighting those that are appropriate for the preclinical evaluation of novel therapies, thereby facilitating further drug development for rare diseases.
Insights
This study compiles mammalian animal models for rare diseases, aiding the development of new treatments. It evaluates model suitability for preclinical drug testing in metabolic, neuromuscular, and ophthalmological conditions.
Area of Science:
- Rare disease research
- Translational medicine
- Preclinical drug development
Background:
- Animal models are crucial for rare disease treatment discovery due to small patient populations.
- Evaluating therapeutic candidates in rare diseases necessitates reliable preclinical models.
- Orphan-designated conditions require specialized models for effective research.
Purpose of the Study:
- To compile and review mammalian animal models for rare diseases.
- To assess the predictive value, advantages, and limitations of these models.
- To guide the selection of appropriate models for preclinical therapy evaluation.
Main Methods:
- Compilation of data from the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) since 2000.
- Literature review to identify and gather information on relevant animal models.
- Analysis of model characteristics for preclinical drug development suitability.
Main Results:
- A comprehensive list of mammalian animal models for orphan conditions was created.
- The predictive value and limitations of various models were discussed.
- Models were highlighted based on their appropriateness for preclinical testing.
Conclusions:
- Appropriate animal models are essential for advancing drug development in rare diseases.
- This compilation facilitates the selection of suitable models for preclinical studies.
- Further development of novel therapies for rare diseases is supported by this resource.
